Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will new biomarkers lead to "golden age" for mental health disorder diagnosis?

This article was originally published in Clinica

Executive Summary

Diagnosis of mental disorders, such as schizophrenia and depression, is slow, complicated and imprecise. Medtech firms are working to smooth the process with the development of definitive biomarker-based diagnostics with the aim of enabling earlier intervention and monitoring therapy to minimise side-effects. Phil Greenfield investigates

You may also be interested in...



RSNA 2019: AI, Machine Learning Continue To Dominate Developments In Radiology

Artificial intelligence (AI) and machine learning took center stage at this year’s Radiological Society of North America meeting in Chicago, and the pervasiveness of AI tech in new product launches was further emphasized at the RSNA’s expanded AI Showcase exhibit.

AHA 2019: Cardiawave Sees Positive Early Results For Non-Invasive Valve Disease Treatment

The French start-up claims first-in-man success for heart valve “softening” treatment and plans further trials for an EU launch.

Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer

The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.

Topics

UsernamePublicRestriction

Register

MT095575

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel